AVTX Avalo Therapeutics, Inc.
Mergers ·
Avalo can pay $5.125 million in cash or stock within 90 days instead of $15 million owed when a Phase 3 trial doses its first patient. If it does not, the milestone amount becomes $12.75 million.
Avalo ended an earlier $50.0 million sales agreement with Oppenheimer. Its stock last sold at $3.72 on May 29, 2025.
Avalo Therapeutics is a clinical-stage biotechnology company developing IL-1β-based treatments for immune-mediated inflammatory diseases. Its lead product candidate, abdakibart (AVTX-009), is an anti-IL-1β monoclonal antibody in the Phase 2 LOTUS trial in hidradenitis suppurativa (HS), a chronic inflammatory skin disease. The randomized, double-blind, placebo-controlled trial evaluates abdakibart in approximately 250 adults with moderate to severe HS, and the company expected to report topline data in the second quarter of 2026. The company plans to prepare for pivotal trials after the readout. Abdakibart is subject to a worldwide exclusive license from Eli Lilly and Company, and the company is responsible for its development and commercialization, with milestone and royalty obligations to Lilly. Several legacy programs, including quisovalimab (AVTX-002), are not being pursued clinically, and the company is exploring strategic alternatives for them.
| Product or program | What it is | Stage |
|---|---|---|
| Abdakibart (AVTX-009) | Anti-IL-1β monoclonal antibody for hidradenitis suppurativa | Phase 2 (LOTUS trial) |
| Quisovalimab (AVTX-002) | Fully human monoclonal antibody directed against LIGHT | legacy program; not being clinically developed |
| AVTX-913 | Nucleotide prodrug for the treatment of a mitochondrial disorder | preclinical |
| Line | FY2025 | FY2024 |
|---|---|---|
| Net income (loss) | -$78.3 million | -$35.1 million |
| Cash from operations | -$51.5 million | -$49.1 million |
| Cash and equivalents | $15.9 million | $134.5 million |
| Short-term investments | $82.5 million | $0 |
Our latest story on this, dated Jun 5, 2025: "Avalo Therapeutics sets up $75,000,000 at-the-market program with TD Cowen". The story links the filing or release it is based on. Read the story.
Avalo Therapeutics, Inc. trades under the ticker AVTX on NASDAQ.
Avalo Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:C6K0.
The SEC Central Index Key (CIK) for Avalo Therapeutics, Inc. is 1534120. Its filings are on SEC EDGAR.
53,629,989 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Avalo Therapeutics, Inc. under United States.
Our directory classifies Avalo Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Avalo Therapeutics, Inc. is US05338F3064.
aibio.space lists Avalo Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Avalo Therapeutics is a clinical-stage biotechnology company developing IL-1β-based treatments for immune-mediated inflammatory diseases. Its lead product candidate, abdakibart (AVTX-009), is an anti-IL-1β monoclonal antibody in the Phase 2 LOTUS trial in hidradenitis suppurativa (HS), a chronic inflammatory skin disease.
Abdakibart (AVTX-009): Anti-IL-1β monoclonal antibody for hidradenitis suppurativa Stage: Phase 2 (LOTUS trial).
Quisovalimab (AVTX-002): Fully human monoclonal antibody directed against LIGHT Stage: legacy program; not being clinically developed.
Avalo Therapeutics, Inc. reported a net loss of $78.3 million for the fiscal year ended Dec 31, 2025, and used $51.5 million of cash in operations, per its annual report to the SEC.
$400.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,3.03,5.02,5.03,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio